1. AI bleeding monitoring in laparoscopic and robotic surgery remains promising but not yet clinically validated
A Journal of Robotic Surgery systematic review assessed AI methods for bleeding prediction, detection, localization, tracking, and blood-loss estimation during conventional and robot-assisted laparoscopy. Reported performance was technically encouraging, with several studies suggesting high detection accuracy and possible real-time use in controlled conditions. The limitation is clinically important: most evidence still comes from small, single-center, retrospective, experimental, or simulation-based datasets. Prospective multi-institutional validation and low-latency operating-room integration are still needed.
Relevance: Bleeding is a critical safety event in advanced laparoscopy, especially HPB, colorectal, gynecologic, and reoperative surgery. This review helps surgeons judge AI bleeding alerts as promising research tools, not yet mature safety systems.
Source: https://pubmed.ncbi.nlm.nih.gov/42174321/
2. Collaborative robotic assistance reduced variability in laparoscopic cholecystectomy operative time
A prospective registry study compared 79 Maestro-assisted laparoscopic cholecystectomies with 79 conventional cases from the same team. Postoperative outcomes were comparable, with no device-related complications or conversions. The main finding was a 35% reduction in operative-time variability rather than a major reduction in mean duration. The system is a bedside co-manipulated platform designed to improve visualization, stability, and ergonomics while preserving standard laparoscopic technique. Two authors reported advisory or equity relationships with the device company, so independent validation is essential.
Relevance: In high-volume laparoscopic cholecystectomy, predictable operative flow may improve scheduling, team workload, and theatre efficiency. The clinical signal is workflow stability, not superiority of dissection or outcomes.
Source: https://pubmed.ncbi.nlm.nih.gov/42174318/
3. Large MBSAQIP analysis defines early suboptimal weight loss after bariatric procedures
An Obesity Surgery study analyzed 166,843 MBSAQIP patients with six-month follow-up. Suboptimal early weight loss was defined as less than 10% total weight loss at six months and occurred in 12.6% overall. Rates were lower after primary surgical procedures, about 7-13%, and higher after endoscopic bariatric interventions, about 34-50%. Predictors included female sex, higher baseline BMI, older age, diabetes, and Black race, but model performance using clinical variables alone was modest, with AUROC about 0.57-0.60.
Relevance: Bariatric surgeons need early pathways for patients with inadequate response, particularly as GLP-1 therapy becomes an adjunct to surgery. These data give useful counseling numbers but show that demographics alone cannot reliably predict individual response.
Source: https://pubmed.ncbi.nlm.nih.gov/42174245/
4. Early semaglutide after laparoscopic sleeve gastrectomy improved one-year weight loss in a non-randomized study
A prospective single-center study evaluated semaglutide started one month after laparoscopic sleeve gastrectomy and continued to six months in patients with BMI at least 35 kg/m2. At 12 months, total weight loss was greater with adjunctive semaglutide than sleeve alone, 35.14% versus 30.73%, and excess weight loss was also higher, 86.42% versus 76.87%. Metabolic improvement was broadly comparable. Because the study was non-randomized, the result should be treated as hypothesis-generating.
Relevance: Postoperative pharmacotherapy is becoming part of metabolic surgery strategy. This supports discussion of early GLP-1 use in selected sleeve patients, while randomized data are still needed on timing, duration, nutrition, cost, and durability.
Source: https://pubmed.ncbi.nlm.nih.gov/42174244/
